Jonathan Erlich, MD
Gastroenterology · Chicago, ILNPI 1265796429
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,495 of the $13,170 with a category attached, or 72.1%. It is spread thinly across 38 manufacturers, the largest accounting for just 23.4%. 2025 is the largest year on record at $5,617, more than ten times the $284 reported in 2019.
Across 530 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Capsovision, Inc.$3K
- Johnson & Johnson$2K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Medtronic$428
- plus $4K from 32 others
Across 13 payments — averaging $5689.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$74K
What the payments were for
- Consulting fees$3,08323%
- Food & beverage$9,49572%
- Education$5914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Capsovision, Inc. | 1 | $3,083 |
| Johnson & Johnson | 79 | $1,796 |
| AbbVie | 115 | $1,761 |
| Takeda Pharmaceuticals U.S.A., Inc. | 120 | $1,296 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 67 | $1,006 |
| Medtronic | 8 | $428 |
| Pfizer | 20 | $410 |
| Neuraxis, Inc. | 1 | $386 |
| Endogastric Solutions, Inc | 3 | $373 |
| Madrigal Pharmaceuticals | 14 | $285 |
| Sanofi | 8 | $215 |
| Lilly USA, LLC | 8 | $190 |
| Gilead | 5 | $185 |
| Braintree Laboratories, Inc. | 9 | $172 |
| Bristol Myers Squibb | 7 | $153 |
| Merck | 6 | $151 |
| Ardelyx, Inc. | 8 | $146 |
| Ipsen Biopharmaceuticals, Inc | 7 | $128 |
| Regeneron Healthcare Solutions, Inc. | 4 | $117 |
| Lucid Diagnostics Inc. | 1 | $108 |
| Intercept Pharmaceuticals, Inc. | 6 | $100 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Celltrion USA Inc. | 3 | $78 |
| QOL Medical, LLC | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Laborie Medical Technologies Corp. | 2 | $56 |
| Echosens North America, Inc. | 3 | $51 |
| Redhill Biopharma Inc. | 2 | $50 |
| Exact Sciences | 2 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Enterra Medical, Inc. | 2 | $29 |
| Evoke Pharma, Inc. | 1 | $26 |
| Organon | 1 | $25 |
| Amgen | 1 | $22 |
| Axonics, Inc. | 1 | $16 |
| Medspira, LLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,170 in reported general payments places this provider in the 85th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $410,100 |
| XifaxanRifaximin | 13 | $38,743 |
| LinzessLinaclotide | 20 | $10,725 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 53 | $8,713 |
| VoqueznaVonoprazan Fumarate | 13 | $8,117 |
| Mesalamine | 23 | $7,723 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 219 | $5,775 |
| Omeprazole | 540 | $5,403 |
| Balsalazide Disodium | 23 | $3,920 |
| Tetracycline Hcl | 15 | $2,323 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 18 | $2,220 |
| Mesalamine ErMesalamine | 11 | $1,600 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 24 | $1,515 |
| Colestipol Hcl | 19 | $1,455 |
| Pantoprazole Sodium | 120 | $1,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,796 | $410,10016 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,006 | $38,74313 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $172 | $10,93471 claims |
| AbbVieLinzess | $1,761 | $10,72520 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $58 | $8,11713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Chicago
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
- Christopher ChapmanChicago$645K
- Saurabh KapurChicago$532K
- Ikuo HiranoChicago$457K
- Adam SteinChicago$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.